Singapore has approved a second oral antiviral drug for treating COVID-19.
Molnupiravir, branded as Lagevrio, was granted interim authorization under the Pandemic Special Access Route (PSAR) by the Health Sciences Authority (HSA) on April 19.
The medicine was approved for treating mild to moderate COVID-19 patients aged 18 and above, who are at risk of developing severe illness or hospitalization, and in whom “alternative COVID-19 treatment options are not clinically appropriate,” according to the HSA.
Lagevrio should be taken within five days of experiencing symptoms for a duration of five days.
“It will be prescribed and prioritized to those at higher risk of severe disease, as directed by the Ministry of Health,” said the authority.
…